

# Association between matrix-metalloproteinase polymorphisms and prostate cancer risk: a meta-analysis and systematic review

Hongxing Zhou<sup>1</sup>  
Xuming Zhu<sup>2</sup>

<sup>1</sup>Department of Clinical Laboratory, Changzhou Second Hospital affiliated to Nanjing Medical University, Changzhou, Jiangsu Province, China; <sup>2</sup>Department of Clinical Laboratory, Wuxi People's Hospital affiliated to Nanjing Medical University, Wuxi, Jiangsu Province, China

**Background:** Data from published articles on the relationship between MMP polymorphisms and prostate cancer risk are conflicted and inconclusive, so a meta-analysis and systematic review were performed to assess the relationship.

**Methods:** Relevant research articles were identified from databases using a search strategy. Studies with the same MMP polymorphisms that could be quantitatively synthesized were included in the meta-analysis. Five comparison models (homozygote, heterozygote, dominant, recessive, and additive) were applied, and a subgroup analysis by case-group sample type was performed. Studies with different polymorphisms that could not be quantitatively synthesized were included in the systematic review.

**Results:** Eleven articles encompassing 22 studies involving 12 MMP polymorphisms were included in this paper. Among the studies included, 13 studies involving MMP1 rs1799750, MMP2 rs243865, and MMP7 rs11568818 were quantitatively synthesized for meta-analysis, and the other nine studies involving nine polymorphisms (MMP2 rs2285053, MMP2 rs1477017, MMP2 rs17301608, MMP2 rs11639960, MMP3 11715A/6A, MMP3 1161A/G, MMP3 5356A/G, MMP9 rs17576, and MMP13 rs2252070) were included in the systematic review. Meta-analysis showed no associations between MMP1 rs1799750, MMP2 rs243865, or MMP7 rs11568818 and prostate cancer risk overall. Subgroup analysis by case-group sample type confirmed that no associations existed. The systematic review suggested that MMP3 11715A/6A and MMP9 rs17576 were associated with prostate cancer risk.

**Conclusion:** MMP polymorphisms are not associated with prostate cancer risk, except for MMP3 11715A/6A and MMP9 rs17576. However, it is necessary to conduct larger-scale, high-quality studies in future.

**Keywords:** matrix metalloproteinase, polymorphism, prostate cancer, meta-analysis

## Introduction

A complex disorder resulting from the combined effects of multiple environmental and genetic factors, prostate cancer is the second-leading cause of cancer death in men.<sup>1</sup> The underlying etiology of prostate cancer is still poorly understood. Genome-wide association studies on the genetic etiology of cancer have discovered some heritability of different cancer types.<sup>2</sup> Single-nucleotide substitution, a kind of alteration in genetic sequence, can lead to cancer formation through biologically regulating a handful of molecular activities.<sup>3</sup>

A family of zinc endopeptidases, MMPs can cleave nearly all components of the extracellular matrix, as well as many other soluble and cell-associated proteins.<sup>4</sup> MMPs

Correspondence: Xuming Zhu  
Department of Clinical Laboratory, Wuxi People's Hospital Affiliated to Nanjing Medical University, 299 Qingyang Road, Wuxi, Jiangsu 214023, China  
Tel +86 150 5223 3796  
Email 7091159@qq.com

play important roles in cancer development, invasion, and metastasis.<sup>5</sup> At the genetic level, a number of studies have been carried out to assess associations between polymorphisms of MMPs and prostate cancer risk,<sup>6–14</sup> but conclusions have been conflicting and inconclusive. For example, Srivastava et al found the MMP2 rs243865 polymorphism contributed to prostate cancer susceptibility,<sup>10</sup> while Adabi et al found no association between MMP2 rs243865 polymorphism and prostate cancer risk.<sup>11</sup> Individual studies with small samples may result in incorrect conclusions. Therefore, a comprehensive meta-analysis and systematic review were necessary to assess relationships between MMP polymorphisms and prostate cancer risk precisely.

## Methods

### Search strategy

The entire process of this meta-analysis and systematic review followed the guidelines of the PRISMA (preferred reporting items for systematic reviews and meta-analyses) statement (Table S1).<sup>15</sup> The databases PubMed, Embase, and Web of Knowledge were searched with the following search terms: (MMP OR MMPs OR matrix metalloproteinase OR matrix metalloproteinases) AND (polymorphism OR polymorphisms OR single nucleotide polymorphism OR single nucleotide polymorphisms) AND (prostate cancer OR prostate carcinoma). The last search was on August 3, 2018. Additional published data were identified by reviewing references listed in each article. The literature search was performed by two investigators independently. Disagreement was resolved by discussion.

### Inclusion and exclusion criteria

Inclusion criteria for this study were a focus on associations between MMP polymorphisms and prostate cancer risk, case–control design, available frequency of each genotype provided in both case and control groups to calculate OR and corresponding 95% CI, and written in English. Exclusion criteria were reviews, editorials, comments, and animal studies and overlap with another included article.

### Data extraction

Two investigators independently extracted author names, year of publication, country of origin, case–group sample type, source of control group, genotyping method, type of MMPs, names of polymorphisms, number of cases and controls, Hardy–Weinberg equilibrium (HWE) values, and frequency of genotypes. Consensus on extracted items was reached by discussion between the two investigators.

## Quality assessment

The quality of each included study was assessed according to the quality-assessment criteria in Table S2.<sup>16</sup> Quality scores of studies ranged from 0 to 15, and studies with scores  $\geq 9$  were regarded as being of high quality.


## Statistical analysis

Meta-analysis was performed unless at least two studies concerning the same MMP polymorphism were included; otherwise, a systematic review was carried out. Pooled ORs and 95% CIs were calculated under five comparison models: homozygote, heterozygote, dominant, recessive, and additive. Pooled ORs assessed by *Z*-test were considered significant at  $P < 0.05$ . HWE in the control group was checked by  $\chi^2$  test, and disequilibrium was deemed present at  $P < 0.05$ . Heterogeneity assumption was checked by a  $\chi^2$ -based *Q*-statistic test and quantified by *I*<sup>2</sup> values. If  $I^2 < 50\%$  or *Q*-test  $P > 0.10$ , the -effect model was used. Otherwise, a random-effect model was used. Subgroup analysis by case–group sample type was also performed. Funnel plots and Egger's test were undertaken to examine publication bias. Publication bias was considered at  $P < 0.05$  for Egger's test. Statistical analyses for this paper were completed with Stata (College Station, TX, USA) version 12.0.

## Results

### Literature search and study characteristics

Figure 1 shows the selection process. A total of 26 articles were identified through the search strategy.<sup>6–14,17–33</sup> Nine articles were removed based on the title or abstract,<sup>17–25</sup> and



**Figure 1** Flow diagram of study-selection process.

the 17 remaining articles were screened for full text. Among these 17 articles,<sup>6–14,26–33</sup> only eleven met inclusion criteria, because four did not have a control group,<sup>26–29</sup> one overlapped with another,<sup>30</sup> and one did not provide available frequency of each genotype in either the case group or control group.<sup>31</sup> Ultimately, eleven articles encompassing 22 studies<sup>6–14,32,33</sup> and involving 12 polymorphisms were included in this paper. Their characteristics are listed in Table 1. Definitions of comparison models for the studies are listed in Table S3, and frequencies of genotypes from the meta-analysis and systematic review in Tables S4 and S5, respectively.

Among the included studies, 13 studies with three polymorphisms (five for MMP1 rs1799750 involving 853 prostate cancer cases and 1,027 controls, six for MMP2 rs243865 involving 699 prostate cancer cases and 734 controls, and two for MMP7 rs11568818 involving 297 prostate cancer cases and 297 controls) were quantitatively synthesized for meta-analysis.<sup>6,8–10,12–14,32,33</sup> The remaining nine studies with nine polymorphisms (MMP2 rs2285053, MMP2 rs1477017, MMP2 rs17301608, MMP2 rs11639960, MMP3 1171-5A/6A, MMP3 1161A/G, MMP3 5356A/G, MMP9 rs17576, and MMP13 rs2252070) involving 2,054 prostate cancer cases and 2,138 controls could not be quantitatively synthesized, and so the systematic review was performed.<sup>7,8,10,11,33</sup>

## Meta-analysis

The results of meta-analysis for MMP1 rs1799750 (Table 2, Figure 2) showed that no significant associations were found in overall people (homozygote model, OR 1.16, 95% CI 0.91–1.47,  $P=0.237$ ; heterozygote model, OR 1.12, 95% CI 0.94–1.33,  $P=0.223$ ; dominant model, OR 1.09, 95% CI 0.94–1.27,  $P=0.251$ ; recessive model, OR 1.09, 95% CI 0.87–1.37,  $P=0.471$ ; additive model, OR 1.09, 95% CI 0.97–1.23,  $P=0.163$ ). When the studies were stratified according to blood samples of case groups (Table 2, Figure 2), no associations existed in any comparison model. Subgroups of tissue samples could not be assessed, because there was only one study included.

For the MMP2 rs243865 polymorphism (Table 3, Figure 3), meta-analysis showed no significant associations were found in people overall (homozygote model, OR 1.00, 95% CI 0.84–1.20,  $P=0.97$ ; heterozygote model, OR 1.08, 95% CI 0.84–1.40,  $P=0.54$ ; dominant model, OR 1.01, 95% CI 0.87–1.18,  $P=0.875$ ; recessive model, OR 0.90, 95% CI 0.76–1.06,  $P=0.206$ ; additive model, OR 0.96, 95% CI 0.86–1.08,  $P=0.521$ ). Subgroup analysis by case-group sample type confirmed that no associations existed in any comparison model matter for blood or tissue samples (Table 3, Figure 3).

For MMP7 rs11568818 (Table 4, Figure 4), no significant associations were found in people overall (homozygote model, OR 0.95, 95% CI 0.67–1.37,  $P=0.796$ ; heterozygote model, OR 0.98, 95% CI 0.72–1.33,  $P=0.908$ ; dominant model, OR 0.99, 95% CI 0.77–1.26,  $P=0.917$ ; recessive model, OR 0.91, 95% CI 0.66–1.27,  $P=0.592$ ; additive model, OR 0.97, 95% CI 0.80–1.17,  $P=0.72$ ). Subgroup analysis by case-group sample type was not performed.

## Heterogeneity analysis

For MMP1 rs1799750, MMP2 rs243865, and MMP7 rs11568818 polymorphisms, there was no obvious heterogeneity in any comparison model for people overall or for subgroup analyses (Tables 2–4).

## Publication-bias analysis

For MMP1 rs1799750, funnel plots (Figure 5) and Egger's tests suggested no evidence of publication bias (homozygote model,  $P=0.27$ ; heterozygote model,  $P=0.187$ ; dominant model,  $P=0.199$ ; recessive model,  $P=0.351$ ; additive model,  $P=0.226$ ).

For MMP2 rs243865, funnel plots (Figure 6) and Egger's tests (homozygote model,  $P=0.87$ ; heterozygote model,  $P=0.864$ ; dominant model,  $P=0.879$ ; recessive model,  $P=0.826$ ; additive model,  $P=0.927$ ) suggested no evidence of publication bias in the meta-analysis either.

For MMP7 rs11568818, publication-bias analysis was not conducted for the two studies involved.

## Systematic review

In the systematic review (Table 5), two polymorphisms (MMP3 1171-5A/6A and MMP9 rs17576) were reported to be associated with prostate cancer risk, while another seven polymorphisms (MMP2 rs2285053, MMP2 rs1477017, MMP2 rs17301608, MMP2 rs11639960, MMP3 1161A/G, MMP3 5356A/G, and MMP13 rs2252070) were not associated with prostate cancer risk.

## Discussion

Srivastava et al showed that MMP2 rs243865 polymorphism contributed to prostate cancer susceptibility,<sup>10</sup> while Adabi et al showed no association between MMP2 rs243865 polymorphism and prostate cancer risk.<sup>13</sup> Therefore, a comprehensive meta-analysis and systematic review were necessary. As a powerful tool for summarizing different studies, meta-analysis and systematic review refer to the use of statistical techniques to integrate results of included studies.<sup>15</sup>

**Table 1** Characteristics of included studies


Study	Year	Country	Case-group sample type	Control-group source	Genotyping method	MMP	Polymorphism	Sample size (case/control)	HWE	Quality score
Albayrak et al <sup>6</sup>	2007	Turkey	Blood	HB	PCR-RFLP	MMP1	rs1799750	55/43	<0.01	7
Jacobs et al <sup>7</sup>	2008	USA	Blood	ND	MassArray	MMP2	rs1477017	1,417/1,441	0.182	9
Jacobs et al <sup>7</sup>	2008	USA	Blood	ND	MassArray	MMP2	rs17301608	1,414/1,432	0.773	9
Jacobs et al <sup>7</sup>	2008	USA	Blood	ND	MassArray	MMP2	rs11639960	1,410/1,439	0.357	9
dos Reis et al <sup>8</sup>	2009	Brazil	Tissue	HB	TaqMan	MMP1	rs1799750	100/100	0.117	7
dos Reis et al <sup>8</sup>	2009	Brazil	Tissue	HB	TaqMan	MMP2	rs243865	100/100	<0.01	6
dos Reis et al <sup>8</sup>	2009	Brazil	Tissue	HB	TaqMan	MMP7	rs11568818	100/100	0.035	6
dos Reis et al <sup>8</sup>	2009	Brazil	Tissue	HB	TaqMan	MMP9	rs17576	100/100	<0.01	6
Tsuchiya et al <sup>9</sup>	2009	Japan	Blood	PB	Direct sequencing	MMP1	rs1799750	283/251	0.113	13
Srivastava et al <sup>10</sup>	2012	India	Blood	Mixed	PCR-RFLP	MMP2	rs243865	190/200	0.919	10
Srivastava et al <sup>10</sup>	2012	India	Blood	Mixed	PCR-RFLP	MMP2	rs2285053	190/200	0.581	10
Srivastava et al <sup>11</sup>	2013	India	Blood	Mixed	PCR-RFLP	MMP3	1171-5A/6A	150/200	0.235	10
Srivastava et al <sup>11</sup>	2013	India	Blood	Mixed	PCR-RFLP	MMP3	1161A/G	150/200	0.793	10
Srivastava et al <sup>11</sup>	2013	India	Blood	Mixed	PCR-RFLP	MMP3	5356A/G	150/200	0.658	10
Yaykasi et al <sup>12</sup>	2014	Turkey	Blood	HB	PCR-RFLP	MMP2	rs243865	61/46	0.758	6
Adabi et al <sup>13</sup>	2015	Iran	Blood	PB	PCR-RFLP	MMP2	rs243865	102/139	0.885	10
Salavati et al <sup>14</sup>	2017	Iran	Tissue	HB	HRM	MMP2	rs243865	50/54	<0.01	7
Liao et al <sup>32</sup>	2018	China	Blood	HB	PCR-RFLP	MMP1	rs1799750	218/436	0.03	7
Bialkowska et al <sup>33</sup>	2018	Poland	Blood	PB	TaqMan	MMP1	rs1799750	197/197	0.226	8
Bialkowska et al <sup>33</sup>	2018	Poland	Blood	PB	TaqMan	MMP2	rs243865	197/197	0.60	8
Bialkowska et al <sup>33</sup>	2018	Poland	Blood	PB	TaqMan	MMP7	rs11568818	197/197	0.411	8
Bialkowska et al <sup>33</sup>	2018	Poland	Blood	PB	TaqMan	MMP13	rs2252070	197/197	0.943	8

**Abbreviations:** HB, hospital-based; PB, population-based; HWE, Hardy-Weinberg equilibrium; PCR-RFLP, polymerase chain-reaction restricted-fragment-length polymorphism; HRM, high-resolution melting.

**Table 2** Meta-analysis of association between MMP1 rs1799750 and prostate cancer

Comparison model	Subgroup	Studies	OR (95% CI)	$P_{OR}^a$	$I^2$ (%)	$P_{het}^b$
Homozygote	Overall	5	1.16 (0.91–1.47)	0.237	15.9	0.313
	Blood	4	1.06 (0.82–1.37)	0.632	0	0.919
Heterozygote	Overall	5	1.12 (0.94–1.33)	0.223	12.9	0.332
	Blood	4	1.06 (0.87–1.27)	0.575	0	0.648
Dominant	Overall	5	1.09 (0.94–1.27)	0.251	0.4	0.404
	Blood	4	1.04 (0.89–1.22)	0.617	0	0.832
Recessive	Overall	5	1.09 (0.87–1.37)	0.471	0	0.666
	Blood	4	1.03 (0.81–1.31)	0.818	0	0.982
Additive	Overall	5	1.09 (0.97–1.23)	0.163	34.5	0.191
	Blood	4	1.04 (0.91–1.18)	0.57	0	0.871

Notes: <sup>a</sup>P-value of Z-test for OR; <sup>b</sup>P-value of Q-test for heterogeneity.




**Figure 2** Forest plots of MMP1 rs1799750 and prostate cancer risk.

Notes: (A) Homozygote model; (B) heterozygote model; (C) dominant model; (D) recessive model; (E) additive model.

**Table 3** Meta-analysis of association between MMP2 rs243865 and prostate cancer

Comparison model	Subgroup	Studies	OR (95% CI)	$P_{OR}^a$	$I^2$ (%)	$P_{het}^b$
Homozygote	Overall	6	1.0 (0.84–1.20)	0.97	0	0.998
	Blood	4	0.99 (0.81–1.21)	0.92	0	0.986
	Tissue	2	1.06 (0.71–1.56)	0.787	0	0.825
Heterozygote	Overall	6	1.08 (0.84–1.40)	0.54	0	0.894
	Blood	4	1.01 (0.76–1.34)	0.967	0	0.972
	Tissue	2	1.48 (0.82–2.68)	0.919	0	0.777
Dominant	Overall	6	1.01 (0.87–1.18)	0.875	0	0.997
	Blood	4	1.0 (0.84–1.18)	0.963	0	0.994
	Tissue	2	1.08 (0.77–1.50)	0.66	0	0.778
Recessive	Overall	6	0.9 (0.76–1.06)	0.206	0	0.957
	Blood	4	0.91 (0.75–1.09)	0.305	0	0.801
	Tissue	2	0.87 (0.60–1.25)	0.442	0	0.886
Additive	Overall	6	0.96 (0.86–1.08)	0.521	0	0.987
	Blood	4	0.96 (0.85–1.09)	0.511	0	0.892
	Tissue	2	0.98 (0.77–1.26)	0.903	0	0.871

Notes: <sup>a</sup>P-value of Z-test for OR; <sup>b</sup>P-value of Q-test for heterogeneity.




**Figure 3** Forest plots of MMP2 rs243865 and prostate cancer risk.  
**Notes:** (A) Homozygote model; (B) heterozygote model; (C) dominant model; (D) recessive model; (E) additive model.


**Table 4** Meta-analysis of association between MMP7 rs11568818 and prostate cancer

Comparison model	Studies	OR (95% CI)	$P_{OR}^a$	$I^2$ (%)	$P_{het}^b$
Homozygote	2	0.95 (0.67–1.37)	0.796	45.9	0.174
Heterozygote	2	0.98 (0.72–1.33)	0.908	0	0.435
Dominant	2	0.99 (0.77–1.26)	0.917	0	0.39
Recessive	2	0.91 (0.66–1.27)	0.592	53.7	0.142
Additive	2	0.97 (0.80–1.17)	0.72	56	0.132

**Notes:** <sup>a</sup> $P$ -value of Z-test for OR; <sup>b</sup> $P$ -value of Q-test for heterogeneity.




**Figure 4** Forest plots of MMP7 rs11568818 and prostate cancer risk.  
**Notes:** (A) Homozygote model; (B) heterozygote model; (C) dominant model; (D) recessive model; (E) additive model.



**Figure 5** Funnel plots of MMP1 rs1799750 and prostate cancer risk.

**Notes:** (A) Homozygote model; (B) heterozygote model; (C) dominant model; (D) recessive model; (E) additive model.



**Figure 6** Funnel plots of MMP2 rs243865 and prostate cancer risk.

**Notes:** (A) Homozygote model; (B) heterozygote model; (C) dominant model; (D) recessive model; (E) additive model.

This meta-analysis of five studies for MMP1 rs1799750, six studies for MMP2 rs243865 and two studies for MMP7 rs11568818 demonstrated that MMP1 rs1799750, MMP2 rs243865 polymorphisms and MMP7 rs11568818 were not associated with prostate cancer. Subgroup analysis by case-group sample type confirmed that no associations existed in any comparison model. We attributed the negative conclusions of our meta-analysis to two factors: firstly, only articles in English were included, and thus other related articles failed to be included; and secondly,

some lower-quality studies were included, resulting in unconvincing conclusions.

Although this systematic review of nine studies involving nine polymorphisms revealed that MMP3 1171 5A/6A and MMP9 rs17576 were associated with prostate cancer risk, its conclusion needs more research to support it, because each polymorphism had only one study. MMP9 can produce prostate cancer indirectly via triggering TGF $\beta$  activation, because an increase in TGF $\beta$  signaling will lead to cancer development and progression.<sup>34,35</sup>

**Table 5** Systematic review of association between MMPs polymorphisms and prostate cancer

A Homozygote model, Heterozygote model, Dominant model							
MMP	SNP	Homozygote model		Heterozygote model		Dominant model	
		OR(95% CI)	P	OR(95% CI)	P	OR(95% CI)	P
MMP2	rs2285053	0.95 (0.663–1.361)	0.780	0.975 (0.617–1.542)	0.915	0.976 (0.735–1.297)	0.868
MMP2	rs1477017	0.937 (0.807–1.089)	0.398	0.974 (0.842–1.128)	0.726	0.975 (0.876–1.086)	0.646
MMP2	rs17301608	0.929 (0.797–1.083)	0.346	0.960 (0.831–1.109)	0.583	0.969 (0.870–1.080)	0.568
MMP2	rs11639960	0.958 (0.827–1.111)	0.573	0.994 (0.857–1.153)	0.933	0.986 (0.886–1.098)	0.802
MMP3	1171-5A/6A	3.339 (1.035–10.774)	0.044	0.837 (0.530–1.322)	0.446	0.961 (0.629–1.468)	0.853
MMP3	1161A/G	1.068 (0.712–1.603)	0.751	1.096 (0.702–1.711)	0.686	1.042 (0.768–1.413)	0.792
MMP3	5356A/G	1.081 (0.684–1.709)	0.738	1.14 (0.763–1.706)	0.522	1.064 (0.782–1.447)	0.695
MMP9	rs17576	0.025 (0.002–0.242)	0.001	0.444 (0.281–0.702)	0.001	0.449 (0.286–0.705)	0.001
MMP13	rs2252070	0.957 (0.653–1.402)	0.822	0.988 (0.653–1.494)	0.954	0.984 (0.739–1.309)	0.909

B Recessive model, Additive model					
MMP	SNP	Recessive model		Additive model	
		OR(95% CI)	P	OR(95% CI)	P
MMP2	rs2285053	0.812 (0.585–1.125)	0.21	0.91 (0.735–1.125)	0.383
MMP2	rs1477017	0.901 (0.787–1.031)	0.129	0.95 (0.875–1.032)	0.226
MMP2	rs17301608	0.913(0.796–1.048)	0.195	0.951 (0.875–1.034)	0.238
MMP2	rs11639960	0.903 (0.791–1.030)	0.129	0.958 (0.882–1.040)	0.301
MMP3	1171-5A/6A	3.667 (1.145–11.741)	0.029	1.111 (0.765–1.615)	0.581
MMP3	1161A/G	0.997 (0.693–1.433)	0.986	1.026 (0.814–1.292)	0.83
MMP3	5356A/G	0.857 (0.573–1.281)	0.452	0.996 (0.784–1.266)	0.975
MMP9	rs17576	0.2 (0.023–1.743)	0.145	0.437 (0.292–0.653)	0.001
MMP13	rs2252070	0.885 (0.628–1.247)	0.484	0.948 (0.763–1.177)	0.627

We noticed two previous meta-analyses had investigated the relationships of MMP1 rs1799750 or MMP2 rs243865 and prostate cancer risk.<sup>17,18</sup> We read these carefully with great interest. Neither included other MMP polymorphisms, except for MMP1 rs1799750 and MMP2 rs243865.<sup>17,18</sup> For MMP2 rs243865, our meta-analysis did not enroll the study by Jacobs et al, because it did not provide available frequency of genotypes.<sup>7</sup> Conversely, both the previous meta-analyses included this study and thus concluded significant association.<sup>17,18</sup> For MMP1 rs1799750, our paper enrolled two additional studies<sup>32,33</sup> compared with one previous meta-analysis,<sup>17</sup> and obtained a similar result. The major strengths of our paper lie in focusing on the relationship between MMP polymorphisms and prostate cancer risk comprehensively and systematically.

Some limitations still existed in our paper. First, several included studies contained small samples, which could lead to unconvincing conclusions. Second, departure from HWE was detected in some studies. Third, there was a lack of a unified criterion for including studies.

## Conclusion

In summary, our paper shows that MMP polymorphisms are not associated with prostate cancer risk, except for MMP3 1171-5A/6A and MMP9 rs17576. However, it is necessary to conduct more large-scale and high-quality studies in future.

## Disclosure

The authors report no conflicts of interest in this work.

## References

- Collak FK, Demir U, Ozkanli S, Kurum E, Zerk PE. Increased expression of YAP1 in prostate cancer correlates with extraprostatic extension. *Cancer Biol Med*. 2017;14(4):405–413.
- Dai J, Shen W, Wen W, et al. Estimation of heritability for nine common cancers using data from genome-wide association studies in Chinese population. *Int J Cancer*. 2017;140(2):329–336.
- Geng P, Li J, Wang N, et al. PSCA rs2294008 polymorphism with increased risk of cancer. *PLoS One*. 2015;10(8):e0136269.
- Radisky ES, Raeeszadeh-Sarmazdeh M, Radisky DC. Therapeutic potential of matrix metalloproteinase inhibition in breast cancer. *J Cell Biochem*. 2017;118(11):3531–3548.
- Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. *Nat Rev Cancer*. 2002;2(3):161–174.
- Albayrak S, Cangüven O, Gökaş C, Aydemir H, Köksal V. Role of MMP-1 1G/2G promoter gene polymorphism on the development of prostate cancer in the Turkish population. *Urol Int*. 2007;79(4):312–315.
- Jacobs EJ, Hsing AW, Bain EB, et al. Polymorphisms in angiogenesis-related genes and prostate cancer. *Cancer Epidemiol Biomarkers Prev*. 2008;17(4):972–977.
- dos Reis ST, Pontes J, Villanova FE, et al. Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer. *J Urol*. 2009;181(5):2320–2325.
- Tsuchiya N, Narita S, Kumazawa T, et al. Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer. *Oncol Rep*. 2009;22(3):493–439.
- Srivastava P, Lone TA, Kapoor R, Mittal RD. Association of promoter polymorphisms in MMP2 and TIMP2 with prostate cancer susceptibility in North India. *Arch Med Res*. 2012;43(2):117–124.



11. Srivastava P, Kapoor R, Mittal RD. Impact of MMP-3 and TIMP-3 gene polymorphisms on prostate cancer susceptibility in North Indian cohort. *Gene*. 2013;530(2):273–277.
12. Yaykaşlı KO, Kayıkçı MA, Yamak N, et al. Polymorphisms in MMP-2 and TIMP-2 in Turkish patients with prostate cancer. *Turk J Med Sci*. 2014;44(5):839–843.
13. Adabi Z, Mohsen Ziaei SA, Imani M, et al. Genetic polymorphism of MMP2 gene and susceptibility to prostate cancer. *Arch Med Res*. 2015;46(7):546–550.
14. Salavati LS, Tafvizi F, Manjili HK. The association between MMP2 -1306 C > T (rs243865) polymorphism and risk of prostate cancer. *Ir J Med Sci*. 2017;186(1):103–111.
15. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg*. 2010;8(5):336–341.
16. Thakkinstian A, Mckay GJ, Mcevoy M, et al. Systematic review and meta-analysis of the association between complement component 3 and age-related macular degeneration: a HuGE review and meta-analysis. *Am J Epidemiol*. 2011;173(12):1365–1379.
17. Weng H, Zeng XT, Wang XH, Liu TZ, He DL. Genetic Association between *Matrix Metalloproteinases* Gene Polymorphisms and Risk of Prostate Cancer: A Meta-Analysis. *Front Physiol*. 2017;8:975.
18. Liu K, Gu S, Liu X, et al. The MMP2 rs243865 polymorphism increases the risk of prostate cancer: A meta-analysis. *Oncotarget*. 2017;8(42):72933–72938.
19. Haque S, Akhter N, Lohani M, Ali A, Mandal RK. Matrix metalloproteinase-2 -1306 C>T gene polymorphism is associated with reduced risk of cancer: a meta-analysis. *Asian Pac J Cancer Prev*. 2015;16(3):889–896.
20. Liu M, Zhao YY, Yang F, et al. Evidence for a role of GPRC6A in prostate cancer metastasis based on case-control and in vitro analyses. *Eur Rev Med Pharmacol Sci*. 2016;20(11):2235–2248.
21. Ben J, Jin G, Zhang Y, et al. Class A scavenger receptor deficiency exacerbates lung tumorigenesis by cultivating a procarcinogenic microenvironment in humans and mice. *Am J Respir Crit Care Med*. 2012;186(8):763–772.
22. Amankwah EK, Sellers TA, Park JY. Gene variants in the angiogenesis pathway and prostate cancer. *Carcinogenesis*. 2012;33(7):1259–1269.
23. Nangia-Makker P, Wang Y, Raz T, et al. Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. *Int J Cancer*. 2010;127(11):2530–2541.
24. Ahirwar DK, Mittal RD. Re: Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer. S. T. dos Reis, J. Pontes, Jr., F. E. Villanova, P. M. D. Borra, A. A. Antunes, M. F. Dall’oglio, M. Sroug and K. R. M. Leite. *J Urol* 2009; 181: 2320-2325. *J Urol*. 2010;183(3):1258.
25. Jain S, Chakraborty G, Kundu GC. The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis. *Cancer Res*. 2006;66(13):6638–6648.
26. Schweigert D, Valuckas KP, Kovalcis V, Ulys A, Chvatovic G, Didziapetriene J. Significance of MMP-9 expression and MMP-9 polymorphism in prostate cancer. *Tumori*. 2013;99(4):523–529.
27. Jaboin JJ, Hwang M, Lopater Z, et al. The matrix metalloproteinase-7 polymorphism rs10895304 is associated with increased recurrence risk in patients with clinically localized prostate cancer. *Int J Radiat Oncol Biol Phys*. 2011;79(5):1330–1335.
28. Gil Ugarteburu R, Rivas del Fresno M, González Rodríguez I, et al. Matrix metalloproteinase-9 polymorphisms in the diagnosis of prostate cancer. A preliminary experience. *Arch Esp Urol*. 2010;63(2):125–132.
29. dos Reis ST, Villanova FE, Andrade PM, et al. Matrix metalloproteinase-2 polymorphism is associated with prognosis in prostate cancer. *Urol Oncol*. 2010;28(6):624–627.
30. dos Reis ST, Villanova FE, de Andrade PM, et al. Polymorphisms of the matrix metalloproteinases associated with prostate cancer. *Mol Med Rep*. 2008;1(4):517–520.
31. Profile Study Australian Prostate Cancer BioResource (APCB) IMPACT Study, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nat Genet*. 2018;50(7):928–936.
32. Liao CH, Wu HC, Hu PS, et al. The association of matrix metalloproteinase-1 Promoter polymorphisms with prostate cancer in taiwanese patients. *Anticancer Res*. 2018;38(7):3907–3911.
33. Białkowska K, Marciniak W, Muszyńska M, et al. Association of zinc level and polymorphism in MMP-7 gene with prostate cancer in Polish population. *PLoS One*. 2018;13(7):e0201065.
34. Lee C, Jia Z, Rahmatpanah F, et al. Role of the adjacent stroma cells in prostate cancer development and progression: synergy between TGF-β and IGF signaling. *Biomed Res Int*. 2014;2014:502093–8.
35. Dayer C, Stamenkovic I. Recruitment of matrix metalloproteinase-9 (MMP-9) to the fibroblast cell surface by lysyl hydroxylase 3 (LH3) triggers transforming growth factor-β (TGF-β) activation and fibroblast differentiation. *J Biol Chem*. 2015;290(22):13763–13778.

## Supplementary materials

**Table S1** PRISMA checklist

Section/topic	#	Checklist item	Reported on page #
<b>Title</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>Abstract</b>			
Structured summary	2	Provide a structured summary including, as applicable: background, objectives, data sources, study-eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings, systematic review registration number.	2–3
<b>Introduction</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	3–4
<b>Methods</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (eg, web address), and if available provide registration information, including registration number.	
Eligibility criteria	6	Specify study characteristics (eg, PICOS, length of follow-up) and report characteristics (eg, years considered, language, publication status) used as criteria for eligibility, giving rationale.	4
Information sources	7	Describe all information sources (eg, databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	4
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	4
Study selection	9	State the process for selecting studies (ie, screening, eligibility, included in systematic review, and if applicable included in the meta-analysis).	4
Data collection process	10	Describe method of data extraction from reports (eg, piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	4
Data items	11	List and define all variables for which data were sought (eg, PICOS, funding sources) and any assumptions and simplifications made.	
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	
Summary measures	13	State the principal summary measures (eg, risk ratio, difference in means).	5
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (eg, $I^2$ ) for each meta-analysis.	5
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (eg, publication bias, selective reporting within studies).	5–6
Additional analyses	16	Describe methods of additional analyses (eg, sensitivity or subgroup analyses, meta-regression) if done, indicating which were prespecified.	5–6
<b>Results</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	6
Study characteristics	18	For each study, present characteristics for which data were extracted (eg, study size, PICOS, follow-up period) and provide the citations.	6–7
Risk of bias within studies	19	Present data on risk of bias of each study, and if available any outcome-level assessment (see item 12).	
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group; (b) effect estimates and confidence intervals, ideally with a forest plot.	7
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	7
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see item 15).	8
Additional analysis	23	Give results of additional analyses, if done (eg, sensitivity or subgroup analyses, meta-regression [see item 16]).	7

(Continued)

**Table S1** (Continued)

Section/topic	#	Checklist item	Reported on page #
<b>Discussion</b>			
Summary of evidence	24	Summarize the main findings, including the strength of evidence for each main outcome; consider their relevance to key groups (eg, health-care providers, users, and policymakers).	9
Limitations	25	Discuss limitations at study and outcome level (eg, risk of bias), and at review level (eg, incomplete retrieval of identified research, reporting bias).	10
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	11
<b>Funding</b>			
Funding	27	Describe sources of funding for the systematic review and other support (eg, supply of data); role of funders for the systematic review.	

**Table S2** Quality-assessment scores

Criteria	Score
Representativeness of case	
Selected from population cancer registry	2
Selected from hospital	1
No method of selection described	0
Representativeness of control	
Population-based	3
Mixed	2
Hospital-based	1
Not described	0
Ascertainment of cancer case	
Histopathological confirmation	2
By patient medical record	1
Not described	0
Control selection	
Controls matched with cases by age and sex	2
Controls matched with cases only by age or by sex	1
Not matched or not described	0
Genotyping examination	
Genotyping done blindly and quality control	2
Only genotyping done blindly or quality control	1
Not described	0
HWE	
HWE in the control group	1
HWD in the control group or not mentioned	0
<b>Total sample size</b>	
>1,000	3
501–1,000	2
201–500	1
≤200	0

**Abbreviations:** HWE, Hardy–Weinberg equilibrium; HWD, HW disequilibrium.

**Table S3** Definition of comparison models

MMP	SNP	Homozygote	Heterozygote	Dominant	Recessive	Additive
MMP1	rs1799750	1G1G vs 2G2G	1G2G vs 2G2G	1G1G+1G2G vs 2G2G	1G1G vs 1G2G+2G2G	1G vs 2G
MMP2	rs243865	CC vs TT	CT vs TT	CC+CT vs TT	CC vs CT+TT	C vs T
MMP2	rs2285053	CC vs TT	CT vs TT	CC+CT vs TT	CC vs CT+TT	C vs T
MMP2	rs1477017	AA vs GG	AG vs GG	AA+AG vs GG	AA vs AG+GG	A vs G
MMP2	rs17301608	CC vs TT	CT vs TT	CC+CT vs TT	CC vs CT+TT	C vs T
MMP2	rs11639960	AA vs GG	AG vs GG	AA+AG vs GG	AA vs AG+GG	A vs G
MMP3	1171-5A/6A	5A5A vs 6A6A	5A6A vs 6A6A	5A5A+5A6A vs 6A6A	5A5A vs 5A6A+6A6A	5A vs 6A
MMP3	1161-A/G	AA vs GG	AG vs GG	AA+AG vs GG	AA vs AG+GG	A vs G
MMP3	5356-A/G	AA vs GG	AG vs GG	AA+AG vs GG	AA vs AG+GG	A vs G
MMP7	rs11568818	AA vs GG	AG vs GG	AA+AG vs GG	AA vs AG+GG	A vs G
MMP9	rs17576	AA vs GG	AG vs GG	AA+AG vs GG	AA vs AG+GG	A vs G
MMP13	rs2252070	TT vs CC	TC vs CC	TT+TC vs CC	TT vs TC+CC	T vs C

**Table S4** Frequency of genotype in studies from meta-analysis. (A) MMP1 rs1799750; (B) MMP2 rs243865; (C) MMP7 rs11568818

<b>A</b>								
First author	MMP	SNP	Case			Control		
			1G1G	1G2G	2G2G	1G1G	1G2G	2G2G
Albayrak S <sup>1</sup>	MMP1	rs1799750	10	7	38	7	3	33
Dos Reis ST <sup>2</sup>	MMP1	rs1799750	21	52	27	11	34	55
Tsuchiya N <sup>3</sup>	MMP1	rs1799750	35	122	126	33	100	118
Liao CH <sup>4</sup>	MMP1	rs1799750	51	88	79	96	193	147
Białkowska K <sup>5</sup>	MMP1	rs1799750	56	105	36	54	90	53
<b>B</b>								
First author	MMP	SNP	Case			Control		
			CC	CT	TT	CC	CT	TT
Dos Reis ST <sup>2</sup>	MMP2	rs243865	50	38	12	59	20	21
Srivastava P <sup>6</sup>	MMP2	rs243865	101	78	11	131	62	7
Yaykasli KO <sup>7</sup>	MMP2	rs243865	51	7	3	42	4	0
Adabi Z <sup>8</sup>	MMP2	rs243865	74	27	0	113	23	1
Shajarehpoor Salavati L <sup>9</sup>	MMP2	rs243865	34	11	5	41	7	6
Białkowska K <sup>5</sup>	MMP2	rs243865	104	79	14	101	78	18
<b>C</b>								
First author	MMP	SNP	Case			Control		
			AA	AG	GG	AA	AG	GG
Dos Reis ST <sup>2</sup>	MMP7	rs11568818	33	41	26	25	39	36
Białkowska K <sup>5</sup>	MMP7	rs11568818	59	100	38	76	97	24

**Table S5** Frequency of genotype in studies from systematic review

First author	MMP	SNP	Case			Control		
			CC	CT	TT	CC	CT	TT
Srivastava P <sup>6</sup>	MMP2	rs2285053	CC	CT	TT	CC	CT	TT
			101	78	11	131	62	7
Jacobs EJ <sup>10</sup>	MMP2	rs1477017	AA	AG	GG	AA	AG	GG
			566	645	206	639	624	178
Jacobs EJ <sup>10</sup>	MMP2	rs17301608	CC	CT	TT	CC	CT	TT
			541	655	218	600	650	182
Jacobs EJ <sup>10</sup>	MMP2	rs11639960	AA	AG	GG	AA	AG	GG
			597	645	168	675	610	154
Srivastava P <sup>11</sup>	MMP3	1171-5A/6A	5A5A	5A6A	6A6A	5A5A	5A6A	6A6A
			11	38	101	4	64	132
Srivastava P <sup>11</sup>	MMP3	1161-A/G	AA	AG	GG	AA	AG	GG
			77	66	7	103	80	17
Srivastava P <sup>11</sup>	MMP3	5356-A/G	AA	AG	GG	AA	AG	GG
			54	84	12	84	89	27
Dos Reis ST <sup>2</sup>	MMP9	rs17576	AA	AG	GG	AA	AG	GG
			1	43	56	5	93	2
Białkowska K <sup>5</sup>	MMP13	rs2252070	TT	CT	CC	TT	CT	CC
			92	87	18	104	78	15

## References

- Albayrak S, Cangüven O, Göktaş C, Aydemir H, Köksal V. Role of MMP-1 1G/2G promoter gene polymorphism on the development of prostate cancer in the Turkish population. *Urol Int.* 2007;79(4):312–315.
- Dos Reis ST, Pontes J Jr, Villanova FE, et al. Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer. *J Urol.* 2009;181(5):2320–2325.
- Tsuchiya N, Narita S, Kumazawa T, et al. Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer. *Oncol Rep.* 2009;22(3):493–439.
- Liao CH, Wu HC, Hu PS, et al. The association of matrix metalloproteinase-1 Promoter polymorphisms with prostate cancer in taiwanese patients. *Anticancer Res.* 2018;38(7):3907–3911.
- Białkowska K, Marciniak W, Muszyńska M, et al. Association of zinc level and polymorphism in MMP-7 gene with prostate cancer in Polish population. *PLoS One.* 2018;13(7):e0201065.
- Srivastava P, Lone TA, Kapoor R, Mittal RD. Association of promoter polymorphisms in MMP2 and TIMP2 with prostate cancer susceptibility in North India. *Arch Med Res.* 2012;43(2):117–1124.
- Yaykaşlı KO, Kayıkçı MA, Yamak N, et al. Polymorphisms in MMP-2 and TIMP-2 in Turkish patients with prostate cancer. *Turk J Med Sci.* 2014;44(5):839–843.
- Adabi Z, Mohsen Ziaei SA, Imani M, et al. Genetic polymorphism of MMP2 gene and susceptibility to prostate cancer. *Arch Med Res.* 2015;46(7):546–550.
- Shajarehpoor Salavati L, Tafvizi F, Manjili HK. The association between MMP2 -1306 C > T (rs243865) polymorphism and risk of prostate cancer. *Ir J Med Sci.* 2017;186(1):103–111.
- Jacobs EJ, Hsing AW, Bain EB, et al. Polymorphisms in angiogenesis-related genes and prostate cancer. *Cancer Epidemiol Biomarkers Prev.* 2008;17(4):972–977.
- Srivastava P, Kapoor R, Mittal RD. Impact of MMP-3 and TIMP-3 gene polymorphisms on prostate cancer susceptibility in North Indian cohort. *Gene.* 2013;530(2):273–277.

### Cancer Management and Research

#### Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes

Submit your manuscript here: <https://www.dovepress.com/cancer-management-and-research-journal>

a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress